Drugs / visepegenatide
visepegenatide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04504370 | Apr 2020 → Mar 2022 | type 2 diabetes mellitus | PegBio Co., Ltd. | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | visepegenatide | “Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel,...” PMID 38948164 ↗ Jun 2024 |
| Known as | PB-119 | “Visepegenatide (PB-119) is a once a week, subcutaneous, glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection without the requirement of dose titration that has shown...” PMID 38948164 ↗ Jun 2024 |
| Known as | Visepegenatida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314895 ↗ |
| Action | Activate | “a once a week, subcutaneous, glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection” PMID 38948164 ↗ Jun 2024 |
| Modality | Protein / enzyme biologic | — CHEMBL5314895 ↗ |
| Route | Subcutaneous | “once a week, subcutaneous” PMID 38948164 ↗ Jun 2024 |